Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul 14:8:316.
doi: 10.3389/fneur.2017.00316. eCollection 2017.

Efficacy and Tolerability of Gabapentin in Adults with Sleep Disturbance in Medical Illness: A Systematic Review and Meta-analysis

Guang Jian Liu  1 , Md Rezaul Karim  1 , Li Li Xu  1 , Song Lin Wang  1 , Chao Yang  2 , Li Ding  1 , Yun-Fu Wang  1
Affiliations

Efficacy and Tolerability of Gabapentin in Adults with Sleep Disturbance in Medical Illness: A Systematic Review and Meta-analysis

Guang Jian Liu et al. Front Neurol. .

Abstract

Background and purpose: The aim of this study was to systematically review the efficacy and tolerability of gabapentin in the treatment of sleep disturbance in patients with medical illness.

Methods: PubMed was searched for randomized, double-blinded, placebo-controlled trials that reported sleep changes during gabapentin treatment up to November 2015.

Findings: This review included 26 studies involving 4,684 participants. Except for Composite Endpoint 3 [standardized mean difference (SMD) = 0.09, 95% confidence interval (CI): -0.05-0.22] compared with the placebo group, the gabapentin group showed superior outcomes on our endpoints: Composite Endpoint 1 (SMD = 0.50, 95% CI: 0.28-0.71), Composite Endpoint 2 (SMD = -0.53, 95% CI: -0.77 to -0.30), Composite Endpoint 4 (SMD = -0.38, 95% CI: -0.58 to -0.19), Composite Endpoint 5 [risk ratio (RR) = 1.79, 95% CI: 1.24-2.58], and Composite Endpoint 6 (RR = 0.48, 95% CI: 0.32-0.72). However, the patients in the gabapentin group showed worse tolerance than those in the placebo group (RR = 1.38, 95% CI: 1.08-1.76).

Implications: This study is the first to systematically assess the clinical value of gabapentin for the treatment of sleep disorders. We found that regardless the type of sleep outcomes, gabapentin displayed stable treatment efficacy for sleep disturbance in patients with medical illness. However, when an average dose of approximately 1,800 mg/day was used, the risk of treatment discontinuation or drug withdrawal was relatively high. We recommend that further studies confirm these findings in patients with primary sleep disorders.

Keywords: efficacy; gabapentin; meta-analysis; sleep disturbance; tolerability.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram of the screening process.
Figure 2
Figure 2
Forest plots of Composite Endpoint 1, Composite Endpoint 2, Composite Endpoint 3, and Composite Endpoint 4. Except for Composite Endpoint 3, the treatment effects of gabapentin were superior to those of the placebo; a random-effects model.
Figure 3
Figure 3
Forest plots of Composite Endpoint 5, Composite Endpoint 6 and Composite Endpoint 7.The treatment effects of gabapentin were superior to those of the placebo; the tolerability of gabapentin was lower than that of the placebo; a random-effects model.
See this image and copyright information in PMC

References

    1. Laugsand LE, Strand LB, Platou C, Vatten LJ, Janszky I. Insomnia and the risk of incident heart failure: a population study. Eur Heart J (2014) 35:1382–93.10.1093/eurheartj/eht019 - DOI - PubMed
    1. Parthasarathy S, Vasquez MM, Halonen M, Bootzin R, Quan SF, Martinez FD, et al. Persistent insomnia is associated with mortality risk. Am J Med (2015) 128:268.e–75.e.10.1016/j.amjmed.2014.10.015 - DOI - PMC - PubMed
    1. Sofi F, Cesari F, Casini A, Macchi C, Abbate R, Gensini GF. Insomnia and risk of cardiovascular disease: a meta-analysis. Eur J Prev Cardiol (2014) 21:57–64.10.1177/2047487312460020 - DOI - PubMed
    1. Daley M, Morin CM, LeBlanc M, Gregoire JP, Savard J. The economic burden of insomnia: direct and indirect costs for individuals with insomnia syndrome, insomnia symptoms, and good sleepers. Sleep (2009) 32:55–64.10.1016/j.sleep.2008.04.005 - DOI - PMC - PubMed
    1. Hillman DR, Lack LC. Public health implications of sleep loss: the community burden. Med J Aust (2013) 199:S7–10.10.5694/mja13.10620 - DOI - PubMed

LinkOut - more resources